Reuters logo
BRIEF-Eagle Pharmaceuticals says it is pursuing development of formulation of Fulvestrant
April 28, 2017 / 9:19 PM / 5 months ago

BRIEF-Eagle Pharmaceuticals says it is pursuing development of formulation of Fulvestrant

April 28 (Reuters) - Eagle Pharmaceuticals Inc

* Eagle Pharmaceuticals Inc says pursuing development of formulation of Fulvestrant that contains no castor oil, requires one monthly injection - SEC filing

* Eagle Pharmaceuticals - with Fulvestrant, belief is that “can eliminate the current warning in the label by conducting the appropriate clinical trial”

* Eagle Pharmaceuticals - in relation to Fulvestran, "hope to achieve a unique J-code", submit NDA in 2018 Source: (bit.ly/2pqq8Xa) Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below